# A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors

Source: https://onco.cc/trials/nct06292208/  
OnCo record `nct06292208` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IBD0333 in advanced solid tumours, run by SUNHO（China）BioPharmaceutical CO., Ltd., now recruiting.

## Summary

A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06292208 by SUNHO（China）BioPharmaceutical CO., Ltd., with 48 participants planned, started 2024-03-09 and due to reach its primary completion in 2029-12-31. Interventions recorded: IBD0333.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06292208
- Phase: 1/2
- Setting: Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) and Preliminary Efficacy of IBD0333 in Patients With Locally Advanced/Metastatic Solid Tumor or Non-Hodgkin Lymphoma
- Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT06292208: https://clinicaltrials.gov/study/NCT06292208

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06292208.json